Retatrutide
Osteoarthritis, Knee
Eli Lilly and Companyprotein_peptidePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
30 Active assets in the Osteoarthritis, Knee cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Duloxetine Orthopaedic Arthroscopy Knee and Shoulder Clinic | Phase 4 | BBB |
Naproxen Pfizer | Phase 3 | BB |
Dfn-15 Pfizer | Phase 4 | BB |
Triamcinalone Mayo Clinic | Phase 4 | BB |
DEXTROSE SOLUTION Kastamonu University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Retatrutide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →